China Cancer Drug Market Overview, 2031

The adoption of cancer drugs in China is heavily influenced by the country’s high cancer burden, rapid healthcare modernization, and government initiatives aimed at improving oncology care access. China accounts for nearly 24% of the global cancer incidence, with over 4.5 million new cases diagnosed annually and more than 3 million deaths reported each year. Lung, liver, colorectal, gastric, and breast cancers represent the most prevalent forms, with an increasing incidence of prostate, pancreatic, and hematological malignancies due to aging, urbanization, and lifestyle shifts. The rising prevalence of cancer places immense operational pressure on hospitals and oncology centers, creating a pressing need for modern and effective drug therapies. China’s healthcare system, although expanding rapidly, still faces disparities in access between tier-1 cities like Beijing, Shanghai, and Guangzhou, and rural regions. Government initiatives, including the “Healthy China 2030” plan and National Cancer Prevention and Control Program, have emphasized early diagnosis, screening, and access to innovative therapies, driving adoption of modern oncology drugs. Additionally, the Chinese government has implemented policy reforms such as the centralized drug procurement program, national reimbursement lists, and accelerated drug approval pathways to enhance patient access and reduce treatment costs. Hospitals are increasingly adopting targeted therapies, immunotherapies, and precision medicine approaches, supported by advances in molecular diagnostics, biomarker testing, and genetic profiling. Participation in international clinical trials is also expanding, providing early access to cutting-edge therapies. Operational constraints, including hospital capacity, staffing, and the need for outpatient care solutions, further drive the modernization of oncology treatment. Overall, China’s high cancer prevalence, government-led policy initiatives, expanding infrastructure, and adoption of precision medicine collectively create a rapidly evolving environment for cancer drug adoption, making China one of the largest and fastest-growing oncology markets globally.

According to the research report, "China Cancer Drug Market Outlook, 2031," published by Bonafide Research, the China Cancer Drug market is anticipated to grow at more than 11.22% CAGR from 2026 to 2031. China’s cancer drug supply ecosystem is a complex network comprising multinational pharmaceutical companies, domestic manufacturers, distributors, and healthcare institutions. While global pharmaceutical giants dominate innovative oncology therapies such as targeted drugs, immunotherapies, and biologics, domestic manufacturers have rapidly expanded capacity to produce generic chemotherapy agents, biosimilars, and supportive care medications. Multinational companies operate in China through joint ventures, wholly owned subsidiaries, and licensing agreements, maintaining a strong presence in major metropolitan areas to supply hospitals and oncology centers. Domestic manufacturers, supported by government incentives and the national “Made in China 2025” initiative, have increasingly improved R&D capabilities, enabling the production of high-quality generics and biosimilars. Distribution is highly structured, with national and regional pharmaceutical wholesalers acting as intermediaries between manufacturers and hospitals, ensuring cold-chain compliance for temperature-sensitive therapies. Specialty distributors and logistics firms play an essential role in delivering high-cost biologics and immunotherapy drugs, often integrating patient support services and infusion management assistance. Hospital pharmacies and oncology centers are key stakeholders, selecting vendors based on supply reliability, after-sales support, clinical guidance, and regulatory compliance. After-sales services, such as pharmacovigilance, training programs for healthcare professionals, and patient adherence programs, are increasingly important for high-cost and complex therapies. The centralization of drug procurement through national tenders also influences vendor selection, as companies must meet strict pricing, quality, and supply reliability criteria. Regional health authorities evaluate suppliers based on both clinical performance and operational capacity, ensuring access to essential therapies across urban and semi-urban areas.

China’s oncology therapy landscape consists of traditional chemotherapy alongside rapidly expanding targeted therapies, immunotherapies, hormonal treatments, and emerging combination modalities. Chemotherapy remains the backbone of cancer treatment, particularly in public hospitals and rural regions, where cost and infrastructure constraints make generics and well-established regimens the preferred choice. These drugs are widely used for lung, breast, colorectal, gastric, and liver cancers and often administered in combination with other therapies. Targeted therapy has seen rapid growth in China due to increasing adoption of biomarker testing, genomic profiling, and precision medicine initiatives. Tyrosine kinase inhibitors, monoclonal antibodies, and small molecule inhibitors are widely used for lung cancer, breast cancer, and hematologic malignancies. Immunotherapy has emerged as a high-growth segment, with immune checkpoint inhibitors, CAR-T therapies, and PD-1/PD-L1 inhibitors being adopted primarily in tier-1 cities and leading oncology hospitals. These therapies have shown promising clinical outcomes in melanoma, lung cancer, and certain hematological cancers. Hormonal therapies remain essential for hormone-sensitive cancers, such as breast and prostate cancer, and are commonly integrated into combination regimens. Emerging treatments, including antibody-drug conjugates, bispecific antibodies, and personalized cell-based therapies, are gradually entering the Chinese market, supported by local clinical trials and international collaborations. China’s regulatory reforms, accelerated approval pathways, and reimbursement expansions have facilitated adoption of these advanced therapies. Hospitals evaluate therapy selection based on efficacy, cost, patient population, and infrastructure capability for complex administration. Overall, China’s therapy mix reflects a dual strategy: traditional chemotherapy dominates in cost-sensitive settings, while advanced targeted and immune-based therapies drive growth in urban and high-capacity hospitals, reflecting the country’s broader modernization of oncology care.

Cancer drug demand in China varies significantly by indication, reflecting both epidemiology and access to modern therapies. Lung cancer represents the largest segment, accounting for nearly 20% of new cancer cases, driven by smoking prevalence and environmental factors; treatment increasingly involves targeted therapies and immunotherapies in urban centers. Breast cancer, particularly among women in metropolitan areas, represents another major segment, with therapy protocols combining chemotherapy, hormonal treatments, targeted therapy, and immunotherapy depending on molecular profiling. Colorectal cancer is also significant, reflecting changing dietary habits, urbanization, and increasing early detection programs; chemotherapy remains dominant, though targeted therapies are growing. Liver cancer, which has a higher incidence in China than in Western countries due to hepatitis prevalence, requires chemotherapy, targeted drugs, and emerging immunotherapies. Prostate cancer and gastric cancer, while less prevalent than lung or liver cancer, still account for substantial drug demand, especially in urban hospitals. Blood cancers such as leukemia, lymphoma, and multiple myeloma are increasingly treated with biologics, targeted therapies, and CAR-T treatments in specialized hospitals. Cervical cancer remains a public health concern, particularly in less urbanized regions, requiring chemotherapy and targeted interventions. Other cancers, including kidney, ovarian, bladder, brain, thyroid, and skin cancers, collectively contribute to the oncology drug market, with specialized centers leading adoption of advanced therapies. Indication-based drug allocation reflects both disease prevalence and regional healthcare capacity, ensuring high-burden cancers receive priority access while emerging therapies expand across less common malignancies. China’s large patient population and varying regional access create a diverse oncology landscape, balancing broad chemotherapy use with growing penetration of targeted and immuno-oncology therapies.

In China, cancer drugs are primarily administered through injectable and oral routes, with each method serving different clinical and operational needs. Injectable therapies dominate for chemotherapy, biologics, and immunotherapy due to the requirement for controlled dosing, infusion monitoring, and safety in hospital settings. Hospitals in tier-1 and tier-2 cities have specialized infusion units equipped to handle intravenous and subcutaneous treatments for aggressive or late-stage cancers, including lung, liver, breast, and hematologic malignancies. These units support complex combination regimens, ensure adverse events are managed promptly, and maintain strict cold-chain compliance for biologics and immunotherapies. Oral therapies are increasingly adopted for targeted drugs and hormonal treatments, providing greater convenience, reducing hospital visits, and supporting patient-centered care. Oral targeted therapies, such as tyrosine kinase inhibitors for lung and colorectal cancer, are particularly important for long-term treatment and maintenance therapy. However, oral administration requires robust patient adherence programs, with hospitals, pharmacies, and digital tools used to monitor compliance and side effects. Physicians often provide structured counseling, follow-up calls, and adherence reminders to ensure treatment efficacy. Combining injectable and oral therapies allows clinicians to tailor regimens based on cancer type, disease stage, and patient preference, balancing clinical effectiveness with operational efficiency. The dual-route approach is particularly important in China, where disparities in hospital infrastructure and regional access influence the adoption of oral therapies outside major urban centers. Overall, injectable and oral administration strategies enable broad coverage of cancer patients while supporting efficient and safe treatment delivery in both public and private healthcare settings.



China’s cancer drug distribution network is multi-tiered, designed to serve both public hospitals and private healthcare providers while maintaining regulatory compliance and cold-chain integrity. Hospital pharmacies are the primary channel, especially for injectable therapies that require professional administration. Public hospitals, including tertiary and specialized oncology centers, procure drugs through centralized provincial or national procurement programs, ensuring access to chemotherapy, targeted therapies, and immunotherapies. Hospital pharmacies manage inventory, dosing schedules, and cold-chain storage, with larger institutions often integrating manufacturer support programs to ensure treatment continuity. Retail pharmacies distribute oral cancer drugs and supportive medications, particularly targeted therapies and hormonal treatments that patients can take at home. Large chain pharmacies and specialty pharmacy networks have expanded capacity to handle high-cost medications, provide patient counseling, and monitor adherence. Online pharmacies are gradually gaining importance for prescription management and home delivery of oral therapies, although regulatory restrictions limit the scale of distribution compared to hospitals and retail outlets. Pharmaceutical distributors and logistics companies are critical in ensuring timely delivery, cold-chain maintenance, and compliance with Good Distribution Practices (GDP). Specialty distributors often partner with hospitals to provide infusion management, patient education, and follow-up support for high-cost biologics. Regional healthcare authorities monitor supply continuity and quality assurance, particularly in semi-urban and rural areas. The integration of hospitals, retail outlets, specialty pharmacies, online platforms, and logistics providers forms a comprehensive distribution network that ensures equitable access to cancer drugs across China’s large and geographically diverse population.
Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Cancer Drug Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Therapy Type
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Hormonal Therapy
• Other Treatment Types
By Indication
• Breast Cancer
• Lung Cancer (Non-Small Cell Lung Cancer and Small Cell Lung Cancer)
• Colorectal Cancer
• Prostate Cancer
• Blood Cancers (Leukemia, Lymphoma, Multiple Myeloma))
• cervical cancer
• Stomach/ Gastric Cancer
• Others (Liver Cancer ,Kidney Cancer (Renal Cell Carcinoma) , ovarian Cancer, Bladder Cancer, Skin Cancer, Brain tumor, Thyroid Cancer )
By Route of Administration
• Oral
• Injectable
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies / Drug Stores
• Online Pharmacies